Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 08 August, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 543904 | NSE: MANKIND

Mankind Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 1, 2025, 2:51 pm

Market Cap 1,06,075 Cr.
Current Price 2,570
High / Low 3,055/1,901
Stock P/E58.7
Book Value 355
Dividend Yield0.00 %
ROCE15.0 %
ROE13.9 %
Face Value 1.00
PEG Ratio5.00

Quick Insight

Mankind Pharma Ltd, based in New Delhi, currently trades at ₹2,570 with a market capitalization of ₹1,06,075 Cr. The company's P/E stands at 58.7, ROE at 13.9%, and ROCE at 15.0%. With an OPM of 26%, Mankind Pharma has shown solid profitability, evident in its net profit of ₹1,945 Cr and healthy reserves of ₹14,599 Cr. The company's leverage is notable, with borrowings amounting to ₹7,254 Cr, while maintaining a healthy interest coverage ratio of 8.28x. However, the high P/BV ratio of 6.98x may indicate an overvaluation in the market. Investors should keep a close watch on the company's growth prospects and management of borrowings to ensure sustained performance in the long term.

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Mankind Pharma Ltd

Competitors of Mankind Pharma Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Mankind Pharma Ltd 1,06,075 Cr. 2,570 3,055/1,90158.7 3550.00 %15.0 %13.9 % 1.00
Industry Average106,075.00 Cr2,570.0058.70355.000.00%15.00%13.90%1.00

All Competitor Stocks of Mankind Pharma Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales 2,0612,2581,9361,8722,0922,2602,2092,0072,4132,5302,4142,1272,541
Expenses 1,6411,7351,5631,4911,5941,6621,6361,4821,8371,7781,6681,6501,868
Operating Profit 420522374381498598573526576752746477673
OPM % 20%23%19%20%24%26%26%26%24%30%31%22%26%
Other Income 196932428784921091251387021964
Interest 9891244472200162147
Depreciation 656671676977908791859110597
Profit before tax 365517326355514601571543603802525429494
Tax % 18%19%24%21%20%21%15%14%16%21%22%11%16%
Net Profit 298420249281409473487468506634412382413
EPS in Rs 7.4410.496.217.0110.2211.8012.1611.6812.6215.849.999.2710.00

Last Updated: August 1, 2025, 6:25 am

Below is a detailed analysis of the quarterly data for Mankind Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

  • For Sales, as of Jun 2025, the value is 2,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,127.00 Cr. (Mar 2025) to 2,541.00 Cr., marking an increase of 414.00 Cr..
  • For Expenses, as of Jun 2025, the value is 1,868.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,650.00 Cr. (Mar 2025) to 1,868.00 Cr., marking an increase of 218.00 Cr..
  • For Operating Profit, as of Jun 2025, the value is 673.00 Cr.. The value appears strong and on an upward trend. It has increased from 477.00 Cr. (Mar 2025) to 673.00 Cr., marking an increase of 196.00 Cr..
  • For OPM %, as of Jun 2025, the value is 26.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Mar 2025) to 26.00%, marking an increase of 4.00%.
  • For Other Income, as of Jun 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 219.00 Cr. (Mar 2025) to 64.00 Cr., marking a decrease of 155.00 Cr..
  • For Interest, as of Jun 2025, the value is 147.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.00 Cr. (Mar 2025) to 147.00 Cr., marking a decrease of 15.00 Cr..
  • For Depreciation, as of Jun 2025, the value is 97.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 105.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 8.00 Cr..
  • For Profit before tax, as of Jun 2025, the value is 494.00 Cr.. The value appears strong and on an upward trend. It has increased from 429.00 Cr. (Mar 2025) to 494.00 Cr., marking an increase of 65.00 Cr..
  • For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 11.00% (Mar 2025) to 16.00%, marking an increase of 5.00%.
  • For Net Profit, as of Jun 2025, the value is 413.00 Cr.. The value appears strong and on an upward trend. It has increased from 382.00 Cr. (Mar 2025) to 413.00 Cr., marking an increase of 31.00 Cr..
  • For EPS in Rs, as of Jun 2025, the value is 10.00. The value appears strong and on an upward trend. It has increased from 9.27 (Mar 2025) to 10.00, marking an increase of 0.73.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 2:25 pm

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 3,9183,8294,7945,5237,4868,1278,6299,498
Expenses 3,1413,1243,5504,1515,6446,4296,3586,930
Operating Profit 7787051,2441,3721,8421,6982,2722,567
OPM % 20%18%26%25%25%21%26%27%
Other Income 2096494154200163369550
Interest 1840118482817372
Depreciation 28386278123270335378
Profit before tax 9416911,2651,4401,8711,5632,2892,367
Tax % 26%26%24%25%26%20%18%18%
Net Profit 6945149581,0841,3891,2481,8761,945
EPS in Rs 17.3312.8323.9227.0734.6831.1646.8447.15
Dividend Payout % 0%0%32%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-25.94%86.38%13.15%28.14%-10.15%50.32%3.68%
Change in YoY Net Profit Growth (%)0.00%112.32%-73.23%14.98%-38.29%60.47%-46.64%

Mankind Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:15%
3 Years:8%
TTM:8%
Compounded Profit Growth
10 Years:%
5 Years:12%
3 Years:8%
TTM:-1%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:22%
Return on Equity
10 Years:%
5 Years:19%
3 Years:17%
Last Year:14%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:43 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 4040404040404041
Reserves 2,9573,0253,6114,6946,5007,7449,66314,599
Borrowings 36019031016885247,254
Other Liabilities 6525968771,0451,7101,5831,7901,934
Total Liabilities 4,0093,8514,5315,8808,9399,37111,51623,828
Fixed Assets 5347789459872,9273,1423,5523,471
CWIP 322211148166387495209207
Investments 1,4021,6981,7842,3972,5263,1024,21516,683
Other Assets 1,7511,1641,6552,3303,1002,6323,5403,467
Total Assets 4,0093,8514,5315,8808,9399,37111,51623,828

Below is a detailed analysis of the balance sheet data for Mankind Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 1.00 Cr..
  • For Reserves, as of Mar 2025, the value is 14,599.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,663.00 Cr. (Mar 2024) to 14,599.00 Cr., marking an increase of 4,936.00 Cr..
  • For Borrowings, as of Mar 2025, the value is 7,254.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2024) to 7,254.00 Cr., marking an increase of 7,230.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 1,934.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,790.00 Cr. (Mar 2024) to 1,934.00 Cr., marking an increase of 144.00 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 23,828.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,516.00 Cr. (Mar 2024) to 23,828.00 Cr., marking an increase of 12,312.00 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 3,471.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,552.00 Cr. (Mar 2024) to 3,471.00 Cr., marking a decrease of 81.00 Cr..
  • For CWIP, as of Mar 2025, the value is 207.00 Cr.. The value appears to be declining and may need further review. It has decreased from 209.00 Cr. (Mar 2024) to 207.00 Cr., marking a decrease of 2.00 Cr..
  • For Investments, as of Mar 2025, the value is 16,683.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,215.00 Cr. (Mar 2024) to 16,683.00 Cr., marking an increase of 12,468.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 3,467.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,540.00 Cr. (Mar 2024) to 3,467.00 Cr., marking a decrease of 73.00 Cr..
  • For Total Assets, as of Mar 2025, the value is 23,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,516.00 Cr. (Mar 2024) to 23,828.00 Cr., marking an increase of 12,312.00 Cr..

Notably, the Reserves (14,599.00 Cr.) exceed the Borrowings (7,254.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +5405379609838211,7991,9832,322
Cash from Investing Activity +-516-306-396-1,127-1,360-1,041-1,919-12,115
Cash from Financing Activity +8-240-55989579-710-99,845
Net Cash Flow31-95-5540485553

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow418.00515.00-2.00-100.00-687.00-4.00-22.00-5.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

No data available for the Financial Efficiency data table.

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters76.50%76.50%76.50%74.88%74.87%
FIIs4.18%4.18%6.74%9.87%11.58%
DIIs4.65%4.56%9.78%11.14%9.94%
Public14.67%14.76%6.97%4.10%3.61%
No. of Shareholders1,31,9181,34,7311,27,4491,35,1161,53,450

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Blue Chip Fund 2,807,055 1.38 599.472,807,0552025-04-22 17:25:130%
Axis ELSS Tax Saver Fund 1,961,633 1.23 418.931,961,6332025-04-22 17:25:130%
Axis Bluechip Fund 1,212,614 0.79 258.971,212,6142025-04-22 11:41:350%
ICICI Prudential Balanced Advantage Fund 1,154,141 0.45 246.481,154,1412025-04-22 17:25:130%
SBI Magnum Midcap Fund 1,123,909 1.46 240.021,123,9092025-04-22 17:25:130%
HDFC Top 100 Fund - Regular Plan 1,044,572 0.7 223.081,044,5722025-04-22 12:29:180%
Nippon India Pharma Fund 900,794 2.7 192.37900,7942025-04-22 17:25:130%
ICICI Prudential Focused Equity Fund 845,691 2.5 180.61845,6912025-04-22 17:25:130%
ICICI Prudential Value Discovery Fund 845,530 0.44 180.57845,5302025-04-22 17:25:130%
ICICI Prudential Equity & Debt Fund 800,648 0.53 170.99800,6482025-04-22 17:25:130%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 49.2847.7532.0035.7831.59
Diluted EPS (Rs.) 49.2047.6832.0035.7831.59
Cash EPS (Rs.) 63.5058.0340.5240.0734.96
Book Value[Excl.RevalReserv]/Share (Rs.) 347.37239.04190.30157.68121.39
Book Value[Incl.RevalReserv]/Share (Rs.) 347.37239.04190.30157.68121.39
Revenue From Operations / Share (Rs.) 295.87257.99218.41194.25155.13
PBDIT / Share (Rs.) 86.1570.2950.6654.5545.41
PBIT / Share (Rs.) 71.1060.3542.5250.3942.44
PBT / Share (Rs.) 60.6959.5241.4148.9341.94
Net Profit / Share (Rs.) 48.4548.0932.3835.9131.99
NP After MI And SOA / Share (Rs.) 48.2547.7532.0035.7831.59
PBDIT Margin (%) 29.1127.2423.1928.0829.27
PBIT Margin (%) 24.0323.3919.4625.9427.35
PBT Margin (%) 20.5123.0618.9525.1827.03
Net Profit Margin (%) 16.3718.6414.8218.4820.61
NP After MI And SOA Margin (%) 16.3018.5014.6518.4220.36
Return on Networth / Equity (%) 13.8920.4317.2423.2826.79
Return on Capital Employeed (%) 13.2724.5621.6930.9433.87
Return On Assets (%) 7.1715.9813.1915.6719.85
Long Term Debt / Equity (X) 0.380.000.000.010.01
Total Debt / Equity (X) 0.590.020.020.140.05
Asset Turnover Ratio (%) 0.610.950.870.981.01
Current Ratio (X) 1.273.102.321.682.89
Quick Ratio (X) 0.892.371.521.012.01
Inventory Turnover Ratio (X) 1.111.210.500.640.57
Interest Coverage Ratio (X) 8.2883.9845.6337.2990.29
Interest Coverage Ratio (Post Tax) (X) 5.6458.4530.1725.5464.60
Enterprise Value (Cr.) 108171.9191239.850.000.000.00
EV / Net Operating Revenue (X) 8.868.830.000.000.00
EV / EBITDA (X) 30.4332.400.000.000.00
MarketCap / Net Operating Revenue (X) 8.198.900.000.000.00
Price / BV (X) 6.989.830.000.000.00
Price / Net Operating Revenue (X) 8.198.900.000.000.00
EarningsYield 0.010.020.000.000.00

After reviewing the key financial ratios for Mankind Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 49.28. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 49.28, marking an increase of 1.53.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 49.20. This value is within the healthy range. It has increased from 47.68 (Mar 24) to 49.20, marking an increase of 1.52.
  • For Cash EPS (Rs.), as of Mar 25, the value is 63.50. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 63.50, marking an increase of 5.47.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 295.87. It has increased from 257.99 (Mar 24) to 295.87, marking an increase of 37.88.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 86.15. This value is within the healthy range. It has increased from 70.29 (Mar 24) to 86.15, marking an increase of 15.86.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 71.10. This value is within the healthy range. It has increased from 60.35 (Mar 24) to 71.10, marking an increase of 10.75.
  • For PBT / Share (Rs.), as of Mar 25, the value is 60.69. This value is within the healthy range. It has increased from 59.52 (Mar 24) to 60.69, marking an increase of 1.17.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 48.45. This value is within the healthy range. It has increased from 48.09 (Mar 24) to 48.45, marking an increase of 0.36.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.25. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 48.25, marking an increase of 0.50.
  • For PBDIT Margin (%), as of Mar 25, the value is 29.11. This value is within the healthy range. It has increased from 27.24 (Mar 24) to 29.11, marking an increase of 1.87.
  • For PBIT Margin (%), as of Mar 25, the value is 24.03. This value exceeds the healthy maximum of 20. It has increased from 23.39 (Mar 24) to 24.03, marking an increase of 0.64.
  • For PBT Margin (%), as of Mar 25, the value is 20.51. This value is within the healthy range. It has decreased from 23.06 (Mar 24) to 20.51, marking a decrease of 2.55.
  • For Net Profit Margin (%), as of Mar 25, the value is 16.37. This value exceeds the healthy maximum of 10. It has decreased from 18.64 (Mar 24) to 16.37, marking a decrease of 2.27.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has decreased from 18.50 (Mar 24) to 16.30, marking a decrease of 2.20.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 13.89. This value is below the healthy minimum of 15. It has decreased from 20.43 (Mar 24) to 13.89, marking a decrease of 6.54.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 13.27. This value is within the healthy range. It has decreased from 24.56 (Mar 24) to 13.27, marking a decrease of 11.29.
  • For Return On Assets (%), as of Mar 25, the value is 7.17. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 7.17, marking a decrease of 8.81.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.38, marking an increase of 0.38.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 0.59, marking an increase of 0.57.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.61. It has decreased from 0.95 (Mar 24) to 0.61, marking a decrease of 0.34.
  • For Current Ratio (X), as of Mar 25, the value is 1.27. This value is below the healthy minimum of 1.5. It has decreased from 3.10 (Mar 24) to 1.27, marking a decrease of 1.83.
  • For Quick Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 2.37 (Mar 24) to 0.89, marking a decrease of 1.48.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.11. This value is below the healthy minimum of 4. It has decreased from 1.21 (Mar 24) to 1.11, marking a decrease of 0.10.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 8.28. This value is within the healthy range. It has decreased from 83.98 (Mar 24) to 8.28, marking a decrease of 75.70.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.64. This value is within the healthy range. It has decreased from 58.45 (Mar 24) to 5.64, marking a decrease of 52.81.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 108,171.91. It has increased from 91,239.85 (Mar 24) to 108,171.91, marking an increase of 16,932.06.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 8.83 (Mar 24) to 8.86, marking an increase of 0.03.
  • For EV / EBITDA (X), as of Mar 25, the value is 30.43. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 30.43, marking a decrease of 1.97.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
  • For Price / BV (X), as of Mar 25, the value is 6.98. This value exceeds the healthy maximum of 3. It has decreased from 9.83 (Mar 24) to 6.98, marking a decrease of 2.85.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
  • For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Mankind Pharma Ltd as of August 8, 2025 is: 2,363.59

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of August 8, 2025, Mankind Pharma Ltd is Overvalued by 8.03% compared to the current share price 2,570.00

Intrinsic Value of Mankind Pharma Ltd as of August 8, 2025 is: 2,641.01

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of August 8, 2025, Mankind Pharma Ltd is Undervalued by 2.76% compared to the current share price 2,570.00

Last 5 Year EPS CAGR: 11.74%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
    1. Net Profit Margin: 16.37%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 13.27% (Industry Average ROCE: 15%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 13.89% (Industry Average ROE: 13.9%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 5.64
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.89
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 58.7 (Industry average Stock P/E: 58.7)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.59
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Mankind Pharma Ltd. is a Public Limited Listed company incorporated on 03/07/1991 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1991PLC044843 and registration number is 044843. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company's Total Operating Revenue is Rs. 9497.80 Cr. and Equity Capital is Rs. 41.26 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals208, Okhla Industrial Estate, Phase-III, New Delhi Delhi 110020investors@mankindpharma.com
http://www.mankindpharma.com
Management
NamePosition Held
Mr. Ramesh JunejaChairman & Wholetime Director
Mr. Rajeev JunejaVice Chairman & Mng.Director
Ms. Sheetal AroraWhole Time Director
Mr. Satish Kumar SharmaWhole Time Director
Mr. Vivek KalraIndependent Director
Mr. Tilokchand Punamchand OstwalIndependent Director
Mr. Bharat AnandIndependent Director
Ms. Vijaya SampathIndependent Director

FAQ

What is the intrinsic value of Mankind Pharma Ltd?

Mankind Pharma Ltd's intrinsic value (as of 07 August 2025) is ₹2363.59 which is 8.03% lower the current market price of 2,570.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,06,075 Cr. market cap, FY2025-2026 high/low of 3,055/1,901, reserves of 14,599 Cr, and liabilities of 23,828 Cr.

What is the Market Cap of Mankind Pharma Ltd?

The Market Cap of Mankind Pharma Ltd is 1,06,075 Cr..

What is the current Stock Price of Mankind Pharma Ltd as on 07 August 2025?

The current stock price of Mankind Pharma Ltd as on 07 August 2025 is 2,570.

What is the High / Low of Mankind Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Mankind Pharma Ltd stocks is 3,055/1,901.

What is the Stock P/E of Mankind Pharma Ltd?

The Stock P/E of Mankind Pharma Ltd is 58.7.

What is the Book Value of Mankind Pharma Ltd?

The Book Value of Mankind Pharma Ltd is 355.

What is the Dividend Yield of Mankind Pharma Ltd?

The Dividend Yield of Mankind Pharma Ltd is 0.00 %.

What is the ROCE of Mankind Pharma Ltd?

The ROCE of Mankind Pharma Ltd is 15.0 %.

What is the ROE of Mankind Pharma Ltd?

The ROE of Mankind Pharma Ltd is 13.9 %.

What is the Face Value of Mankind Pharma Ltd?

The Face Value of Mankind Pharma Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mankind Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE